Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 665

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 665
---
 financial statements; therefore,
actual results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.

The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

SCHEDULE
OF ANTI-DILUTIVE SECURITIES 

    Weighted average 

    For the year ended December 31, 

    2024  
    2023 
  
    Outstanding stock options 
     2,519,419  
     1,979,196 
  
    Warrants 
     3,935,282  
     3,090,787 

Cash
and cash equivalents

The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company’s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.

Property
and equipment

Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of three years for employee-related computers and
other office equipment and five years for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.

Patents

The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.

    F-8

Research
and development expenses

Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes